Sanofi/Regeneron Solidify Lead Over J&J/GSK In IL-6 Inhibition For RA
This article was originally published in The Pink Sheet Daily
Executive Summary
With second pivotal trial of Sanofi/Regeneron's sarilumab, companies move towards filing. Johnson & Johnson and GlaxoSmithKline are close behind with sirukumab, aiming for a 2016 filing.